Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.35
+8.1%
$5.30
$1.67
$7.29
$485.03M0.944.96 million shs6.03 million shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$14.33
+1.3%
$12.51
$4.81
$27.50
$481.40MN/A328,877 shs280,074 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.66
+5.1%
$1.49
$0.89
$3.10
$132.36M-0.21835,539 shs690,192 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.93
+4.8%
$5.74
$2.41
$10.07
$440.74M2.441.16 million shs794,407 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+8.08%+9.18%-19.06%+42.67%+184.57%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
+1.27%-2.65%+4.75%+17.94%+1,432,999,900.00%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+5.06%+12.16%+3.75%+2.47%+71.15%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+4.77%-2.95%-12.28%+111.03%-40.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.5436 of 5 stars
3.61.00.00.03.31.70.6
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
1.9784 of 5 stars
3.50.00.00.01.11.70.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.054 of 5 stars
3.52.00.00.01.81.71.9
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.5465 of 5 stars
4.62.00.00.03.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.17
Buy$23.25334.58% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.63162.56% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00803.61% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.00152.95% Upside

Current Analyst Ratings Breakdown

Latest PLX, MBX, ATYR, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $17.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $13.00
8/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $14.00
8/5/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/21/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$16.00
7/16/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K2,279.33N/AN/A$0.76 per share7.04
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$61.95M2.14$0.09 per share17.80$0.47 per share3.53
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M57.08N/AN/A$3.32 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A-$4.54N/AN/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.07N/A5.35N/A-21.03%-30.89%-11.74%N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)

Latest PLX, MBX, ATYR, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51-$0.42+$0.09-$0.42N/AN/A
8/7/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.22-$0.04-$0.22N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
5.63
5.63
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
9.34
9.34

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5397.99 million94.36 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.59 millionN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.73 million69.00 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.87 million76.39 millionOptionable

Recent News About These Companies

Q3 EPS Forecast for Solid Biosciences Increased by Analyst
Leerink Partnrs Weighs in on SLDB Q1 Earnings
HC Wainwright Brokers Reduce Earnings Estimates for SLDB

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.35 +0.40 (+8.08%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$5.38 +0.03 (+0.47%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$14.33 +0.18 (+1.27%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$14.34 +0.01 (+0.03%)
As of 08/22/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.66 +0.08 (+5.06%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.64 -0.02 (-1.51%)
As of 08/22/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.93 +0.27 (+4.77%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$5.90 -0.03 (-0.57%)
As of 08/22/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.